$HRGN
Harvard Apparatus Regenerative Technology Inc

2016 Q3 Form 10-Q Financial Statement

#000114420416118421 Filed on August 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $26.00K $28.00K $73.00K
YoY Change -29.73% -61.64% 217.39%
Cost Of Revenue $13.00K $44.00K $37.00K
YoY Change -27.78% 18.92% 208.33%
Gross Profit $13.00K -$16.00K $36.00K
YoY Change -31.58% -144.44% 227.27%
Gross Profit Margin 50.0% -57.14% 49.32%
Selling, General & Admin $937.0K $1.230M $3.482M
YoY Change -10.08% -64.68% 161.8%
% of Gross Profit 7207.69% 9672.22%
Research & Development $2.225M $1.680M $1.050M
YoY Change 75.33% 60.0% -13.51%
% of Gross Profit 17115.38% 2916.67%
Depreciation & Amortization $120.0K $110.0K $120.0K
YoY Change 0.0% -8.33% 33.33%
% of Gross Profit 923.08% 333.33%
Operating Expenses $3.162M $2.906M $4.535M
YoY Change 36.82% -35.92% 78.26%
Operating Profit -$3.149M -$2.922M -$4.499M
YoY Change 37.39% -35.05% 77.62%
Interest Expense $100.0K $210.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change
Pretax Income -$3.053M -$2.712M -$4.499M
YoY Change 33.2% -39.72% 77.62%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.053M -$2.712M -$4.499M
YoY Change 33.2% -39.72% 77.62%
Net Earnings / Revenue -11742.31% -9685.71% -6163.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.547M -$3.474M -$8.654M
COMMON SHARES
Basic Shares Outstanding 17.11M shares 14.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.010M $8.100M $10.13M
YoY Change -26.71% -20.04% 0.6%
Cash & Equivalents $6.006M $8.100M $10.13M
Short-Term Investments
Other Short-Term Assets $100.0K $160.0K $170.0K
YoY Change 25.0% -5.88% -52.78%
Inventory $41.00K $50.00K $200.0K
Prepaid Expenses $96.00K
Receivables $66.00K $40.00K $81.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.209M $8.340M $10.58M
YoY Change -26.78% -21.17% -0.66%
LONG-TERM ASSETS
Property, Plant & Equipment $988.0K $1.080M $1.200M
YoY Change -17.8% -10.0% 15.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $988.0K $1.080M $1.200M
YoY Change -17.8% -10.0% 15.61%
TOTAL ASSETS
Total Short-Term Assets $6.209M $8.340M $10.58M
Total Long-Term Assets $988.0K $1.080M $1.200M
Total Assets $7.197M $9.420M $11.78M
YoY Change -25.69% -20.03% 0.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $803.0K $600.0K $320.0K
YoY Change 265.0% 87.5% -26.27%
Accrued Expenses $760.0K $410.0K $220.0K
YoY Change 590.91% 86.36% -37.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.411M $1.940M $590.0K
YoY Change 628.4% 228.81% -28.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.411M $1.940M $590.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.411M $1.940M $590.0K
YoY Change 628.4% 228.81% -28.48%
SHAREHOLDERS EQUITY
Retained Earnings -$32.98M
YoY Change 46.89%
Common Stock $171.0K $110.0K
YoY Change 34.65% 41.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.786M $7.480M $11.19M
YoY Change
Total Liabilities & Shareholders Equity $7.197M $9.420M $11.78M
YoY Change -25.69% -20.04% 0.8%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$3.053M -$2.712M -$4.499M
YoY Change 33.2% -39.72% 77.62%
Depreciation, Depletion And Amortization $120.0K $110.0K $120.0K
YoY Change 0.0% -8.33% 33.33%
Cash From Operating Activities -$2.090M -$1.500M -$2.020M
YoY Change 12.97% -25.74% -15.83%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$90.00K -$10.00K
YoY Change -93.75% 800.0% -96.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$90.00K -$10.00K
YoY Change -93.75% 800.0% -96.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.850M 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.090M -1.500M -2.020M
Cash From Investing Activities -10.00K -90.00K -10.00K
Cash From Financing Activities 0.000 4.850M 0.000
Net Change In Cash -2.100M 3.260M -2.030M
YoY Change 8.81% -260.59% -20.39%
FREE CASH FLOW
Cash From Operating Activities -$2.090M -$1.500M -$2.020M
Capital Expenditures -$10.00K -$90.00K -$10.00K
Free Cash Flow -$2.080M -$1.410M -$2.010M
YoY Change 23.08% -29.85% -6.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Cost Of Revenue
CostOfRevenue
44000 USD
us-gaap Cost Of Revenue
CostOfRevenue
37000 USD
us-gaap Gross Profit
GrossProfit
-16000 USD
us-gaap Gross Profit
GrossProfit
36000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3054000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2235000 USD
us-gaap Operating Expenses
OperatingExpenses
5378000 USD
us-gaap Operating Expenses
OperatingExpenses
7155000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5394000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7119000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5184000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7122000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14822000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9592000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5184000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7130000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5184000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7122000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2324000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4920000 USD
CY2016Q2 us-gaap Revenues
Revenues
28000 USD
CY2015Q2 us-gaap Revenues
Revenues
73000 USD
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
44000 USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
37000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
2906000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
4535000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2712000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4499000 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15535000 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10303000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2712000 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4498000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2712000 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4499000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1230000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3482000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3183000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-66000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-28000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3984000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3710000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
217000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-217000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-21000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
349000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3237000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4845000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8594000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-8000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
644000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4855000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7456000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5272000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8100000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10127000 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
5357000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
76000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-174000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-144000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
9000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2015Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9700000 USD
CY2015Q1 bstg Proceeds From Issuance Of Stock To Underwriters
ProceedsFromIssuanceOfStockToUnderwriters
8600000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3253118 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
822500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
275929 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3799689 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.65
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.08
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Biostage, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001563665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
BSTG
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17108968 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Reclassification</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Sales and marketing expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">83</font> thousand and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million for the three and six months ended June 30, 2015, respectively, have been reclassified to selling, general and administrative expenses to conform to the 2016 presentation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4496000 USD
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17097420 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17097420 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14101395 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14101395 shares
CY2016Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
942000 USD
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-210000 USD
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-210000 USD
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1100000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
150000 shares
CY2016Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
371 USD
CY2016Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
349 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
129 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.741 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y4M24D
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0101 pure
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
942000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
1281000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-339000 USD
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2016Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
129 USD
bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
-210000 USD
bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
0 USD
bstg Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
116000 USD
bstg Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0 USD
CY2016Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
129000 USD
CY2015Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
129000 USD

Files In Submission

Name View Source Status
0001144204-16-118421-index-headers.html Edgar Link pending
0001144204-16-118421-index.html Edgar Link pending
0001144204-16-118421.txt Edgar Link pending
0001144204-16-118421-xbrl.zip Edgar Link pending
bstg-20160630.xml Edgar Link completed
bstg-20160630.xsd Edgar Link pending
bstg-20160630_cal.xml Edgar Link unprocessable
bstg-20160630_def.xml Edgar Link unprocessable
bstg-20160630_lab.xml Edgar Link unprocessable
bstg-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v446200_10q.htm Edgar Link pending
v446200_ex31-1.htm Edgar Link pending
v446200_ex31-2.htm Edgar Link pending
v446200_ex32-1.htm Edgar Link pending
v446200_ex32-2.htm Edgar Link pending